Qure NV (QURE) reports significant progress in Huntington's disease treatment but faces hurdles with FDA approval.

Management stated that the timing of the BLA submission for AMT-130 is now uncertain following recent FDA feedback. Kapusta explained, "the latest FDA feedback is certainly surprising and ...

Three years ago, when Tris Dyson was first diagnosed with amyotrophic lateral sclerosis (ALS), better known as motor neurone ...

Amylyx Pharmaceuticals Inc (AMLX) reports a robust cash position and advances in its lead program, despite challenges in trial timelines.

Q3 2025 Management View Justin Klee, Co-Founder, Co-CEO & Director, announced "Q3 was a quarter of progress as we continue to focus on our lead program, avexitide, in post-bariatric hypoglycemia or ...

SPG302 was well tolerated in a trial, with preliminary data supporting the idea the therapy might slow ALS progression.

Although amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). are very different diseases, they have ...

A year after Neuralink secured FDA approval to test brain implants designed to restore sight, one of its earliest patients has found another use for the ...

Meet Dr. Richard Bedlack, Neurologist and Director of the Amyotrophic Lateral Sclerosis (ALS) program at Duke. He not only ...

Larimar Therapeutics finds itself navigating a complex landscape of groundbreaking clinical progress against a backdrop of mounting financial pressures. The company's lead drug candidate, nomlabofusp, ...

Cash and cash equivalents decreased 4% to $54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by 4% to $26.0 million for the quarter e ...

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in ...